A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
Background: Abiraterone acetate was approved by FDA and EMA in April and September 2011, respectively for treatment of patients with casteration resistant prostate cancer and those previously treated with docetaxel. It is a selective inhibitor of androgen biosynthesis which potentially and irreversi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2018-01-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/818 |